Drug firms upped DTC ad spend in '06

Share this article:
Led by the sleep aid category, drug firms upped consumer advertising by a healthy margin in 2006, data from advertising intelligence firms show. Through October, the spending level for all prescription drugs was on pace for an 8% hike over the first 10 months of 2006, to $3.82 billion from $3.5 billion, according to data from Nielsen Monitor-Plus. The surge was hottest within the top-10 prescription brands, which showed a 36% hike to $1.39 billion from $1.02 billion. Figures from TNS Media Intelligence, another research company, reflect a rise of 10% among the top 10, from $1.09 billion to $1.2 billion during the year’s first nine months vs. the previous year’s. As of press time, data for the full fourth quarter were not available, both data firms said. Driving the increase was Lunesta, which looks set to unseat Nexium as the top DTC spender for the year. Sepracor had increased its DTC outlay for Lunesta by about $120 million or about 70% through October as compared to the same period in 2005, per Nielsen. That translates into $291 million invested to promote Lunesta, whose trademark luna moth has become one of the world’s most recognized brand icon among consumers. AstraZeneca, on the other hand, cut DTC spending in support of heartburn drug Nexium 8% to $165 million for the first 10 months of 2006 vs. the same period in 2005. Some of it may have gone toward a 10% rise in spending for Crestor, as AZ sought to maintain the cholesterol drug’s profile despite safety issues. Among other firms driving the ad splurge, Sanofi-Aventis boosted DTC promotion for its Ambien franchise from $2 million to $160 million to support the launch of a new extended-release version, Ambien CR. The Merck/Schering-Plough joint venture spent 26% more on DTC for Vytorin, perhaps in a bid to capture market share after Merck’s Zocor went off patent in June. And Plavix marketers Sanofi and Bristol-Myers Squibb amped up spending by 15% to lessen the impact from the brief generic clopidogrel launch.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...